Navigation Links
Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer

NEW YORK, April 10, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced that a Phase III study of ERBITUX(R) (Cetuximab) plus gemcitabine (a chemotherapy) in patients with locally advanced unresectable or metastatic pancreatic cancer did not meet its primary endpoint of improving overall survival.

Conducted by the Southwest Oncology Group (SWOG), a cancer center network sponsored by the National Cancer Institute, the open-label, randomized study compared ERBITUX plus gemcitabine to gemcitabine alone in more than 700 patients with pancreatic cancer in the first-line treatment setting. The study was conducted in centers throughout the United States and Canada. It was completed in a significantly shorter time than projected, providing a timely answer to an important research question. SWOG has informed ImClone and Bristol-Myers Squibb that the primary study endpoint of statistically improving overall survival was not met. The three parties -- SWOG, ImClone, and Bristol-Myers Squibb -- will engage in joint efforts to fully interpret these results.

"This study was designed to examine the Phase II results we previously observed for ERBITUX in patients with pancreatic cancer," stated Eric K. Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems. "We still consider pancreatic cancer to be of the utmost priority and we intend to pursue additional evaluations with ERBITUX including a pilot study of ERBITUX and bevacizumab with or without gemcitabine, as well as our pipeline agents, to improve the outcome for patients with pancreatic cancer."

"Pancreatic cancer is a devastating disease with few effective treatment options, and it is unfortunate that the use of ERBITUX in this trial has not demonstrated the benefit it has shown in other tumors," said Martin Birkhofer, M.D., Vice President, Oncology Global Medical Affa
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
3. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/2/2015)... , July 2, 2015   EVO Aesthetic ... the leading provider for non-invasive aesthetics in ... tattoo removal treatments with the Astanza Duality laser. The ... well being through various medical and laser procedures. Their ... unwanted ink a clear solution to their tattoo regret. ...
(Date:7/2/2015)... BURLINGTON, Mass. , July 2, 2015 /PRNewswire/ ... U.S. and European retinal specialists identify less frequent ... macular edema (DME), due to the burden on ... semi-monthly anti-vascular endothelial growth factor (VEGF) injections, which ... compound, Allergan/Molecular Partners, abicipar pegol, which is in ...
(Date:7/2/2015)...  Konica Minolta, Inc. (Konica Minolta) ( Tokyo ... Sawae Technologica Ltda., an X-ray system equipment manufacturer based ... its Brazilian healthcare sales company, Konica Minolta Healthcare do ... Brazil market investment and growth With ... million, significant healthcare technical advancements and efficiencies are required. ...
Breaking Medicine Technology:EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3
... Nov. 8, 2010 Keeping radiation dose in check ... computed tomography (CT), which has undergone some significant technological advances ... CT delivers some of the highest radiation doses in diagnostic ... the appropriate radiation dose can result in unnecessarily high exposures, ...
... Nov. 8, 2010 Epeius Biotechnologies Corporation, a leader ... today the receipt of additional financial support for the ... of Treasury, Health and Human Services (HHS), and the ... a prestigious competitive grant. This latest support for the ...
Cached Medicine Technology:ECRI Institute Service to Address CT Radiation Dose Safety 2ECRI Institute Service to Address CT Radiation Dose Safety 3Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy 2
(Date:7/4/2015)... ... 04, 2015 , ... Chronic Neck Pain. Neck pain is no ... in the neck. Another 19% suffer from head, migraine, or facial pain, in some ... 45% of American workers must deal with neck pain. Strategies for mitigating ...
(Date:7/3/2015)... ... July 03, 2015 , ... On ... for a new SEO training system called "Page One Engine" . The ... generation has received glowing reviews from several well-known marketers. HonestyFirstReviews.com's Tiffany Hendricks has ...
(Date:7/3/2015)... ... 2015 , ... B. E. Smith, the only full-service leadership ... national chief nursing officer recruitment for Jane Phillips Medical Center in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/3/2015)... ... 03, 2015 , ... First Choice Emergency Room , the largest network ... as the new Medical Director of its Frisco facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:7/2/2015)... ... , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its ... in Mississippi. The premium frozen yogurt chain was listed as #22 on the Inc. ... Railroad Avenue, New Albany, MS 38652, will have a grand opening event on July ...
Breaking Medicine News(10 mins):Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:sweetfrog Opens First Location in Mississippi 2
... Senior Living Group Provides New Web-Based Educational Tool, ... and their,adult children now have a new online ... National Assisted Living Week,(September 7-13), Atria Senior Living ... a new website to provide important information to ...
... New York (September 12, 2008) -- Nearly 100 of the ... from public and private sectors will gather in New York ... interventional therapies for the treatment of Type 2 Diabetes. Currently, ... world, affecting an estimated 23.6 million people in the United ...
... for Targeted Prevention Outreach, BOSTON, Sep. 12 ... (CDC) yesterday released a new report showing the,uneven ... color and men who,have sex with men (MSM). ... System," reveals that new infection rates in black,and ...
... with rare eye disease regained partial sight with experimental ... people with a rare, incurable form of hereditary blindness ... new report says. , The patients, all in ... (LCA2), a disease in which photoreceptor cells cannot respond ...
... 12 Research on 445,families centered in two ... 80 percent of adults suffer from more severe ... Ph.D., an expert,on gum disease and associate dean ... Dentistry., "Leaving periodontal disease untreated is a ...
... telephonic counseling and a 24-hour Nurse Helpline established for ... ... (NYSE: WLP ) today,announced revised medical and pharmacy guidelines to ... 24-hour nurse helpline,-- 1-866-417-7107 -- has been established to assist members., ...
Cached Medicine News:Health News:More Older Americans Seeking Online Resources to Plan for Their Future 2Health News:Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes 2Health News:Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes 3Health News:Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes 4Health News:Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes 5Health News:Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes 6Health News:Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes 7Health News:CDC Reports High HIV Infection Rates in Communities of Color, Men Who Have Sex With Men 2Health News:CDC Reports High HIV Infection Rates in Communities of Color, Men Who Have Sex With Men 3Health News:Gene-Transfer Proves Safe for Vision Problem 2Health News:Study Shows High Gum Disease Rates in Rural Appalachia, Sheds Light on Reasons for Tooth Loss 2Health News:Study Shows High Gum Disease Rates in Rural Appalachia, Sheds Light on Reasons for Tooth Loss 3Health News:WellPoint Adjusts Health and Pharmacy Guidelines for Members in Texas and Louisiana Affected by Hurricane Ike 2Health News:WellPoint Adjusts Health and Pharmacy Guidelines for Members in Texas and Louisiana Affected by Hurricane Ike 3
BD Beaver Cataract blade, 30.0 mm long x 2.2 mm wide, designed for ICCE and ECCE procedures, designed for ICCE and ECCE, sterile....
BD Beaver DeBakey blade, 5 mm cutting width, sterile....
... standard trial frames. They are made of optical quality ... box. There are two sets available providing a full ... is that a patient can wear the prism with ... the patient to adapt to the use of the ...
Developed for reconstructive plastic surgery with E-Type coupling. Order blades by size from 12 mm, 25 mm, 50 mm or 75 mm depending on your specific case requirements. Blades come in packs of 10....
Medicine Products: